Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients

被引:8
|
作者
Sader, Helio S. [1 ,2 ]
Fritsche, Thomas R. [1 ]
Jones, Ronald N. [1 ,3 ]
机构
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
Hemodialysis; Daptomycin; Staphylococcus aureus; Catheter infection; Bacteremia; Bloodstream infection; STAGE RENAL-DISEASE; IN-VITRO ACTIVITY; VANCOMYCIN; INFECTIONS; BACTEREMIA; SEPSIS; ACCESS;
D O I
10.1016/j.ijid.2008.07.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Patients on long-term hemodialysis are at a significantly higher risk for catheter-related bloodstream infections (BSI) than the general population. These infections are generally caused by Gram-positive organisms, especially Staphylococcus aureus. In the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations. Methods: The potencies of daptomycin and various comparator agents were evaluated by reference broth microdilution methods for S. aureus bloodstream isolates from dialysis patients (606 strains) in 43 hospitals in North America and Europe. Susceptibility patterns for the dialysis isolate set were compared to those S. aureus causing BSI in other patient populations in the same hospitals and time period. Results: Daptomycin was highly potent against S. aureus causing bacteremia in dialysis patients (MIC50/MIC90, 0.25/0.5 mu g/ml). Vancomycin (MIC50/MIC90, 1/1 mu g/ml) and linezolid (MIC50/MIC90, 2/2 mu g/ml) showed similar potency, and overall susceptibility rates for the three antibiotics were 99.8-100.0% susceptible. Linezolid and vancomycin were four- to eight-fold less potent than daptomycin. Conclusions: The overall susceptibility patterns of S. aureus strains from dialysis patients were very similar to those of non-dialysis patients. (c) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 50 条
  • [41] Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci
    Picazo, Juan J.
    Betriu, Carmen
    Rodriguez-Avial, Iciar
    Culebras, Esther
    Lopez, Fatima
    Gomez, Maria
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2010, 28 (01): : 13 - 16
  • [42] Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers
    Sader, Helio S.
    Farrell, David J.
    Flamm, Robert K.
    Jones, Ronald N.
    SURGICAL INFECTIONS, 2016, 17 (04) : 443 - 447
  • [43] Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)
    Duncan, Leonard R.
    Smart, Jennifer I.
    Flamm, Robert K.
    Sader, Helio S.
    Jones, Ronald N.
    Mendes, Rodrigo E.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 86 (03) : 300 - 302
  • [44] Understanding the antimicrobial activity of selected disinfectants against methicillin-resistant Staphylococcus aureus (MRSA)
    Aboualizadeh, Ebrahim
    Bumah, Violet V.
    Masson-Meyers, Daniela S.
    Eells, Janis T.
    Hirschmugl, Carol J.
    Enwemeka, Chukuka S.
    PLOS ONE, 2017, 12 (10):
  • [45] In Vitro Antimicrobial Activity of Telavancin against Methicillin-resistant Staphylococcus aureus Clinical Isolates from Japan (2006)
    Kazuo Hatano
    Kaoru Matsuzaki
    Yumie Sato
    Intetsu Kobayashi
    Keizo Yamaguchi
    The Journal of Antibiotics, 2007, 60 : 709 - 712
  • [46] In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006)
    Hatano, Kazuo
    Matsuzaki, Kaoru
    Sato, Yumie
    Kobayashi, Intetsu
    Yamaguchi, Keizo
    JOURNAL OF ANTIBIOTICS, 2007, 60 (11): : 709 - 712
  • [47] Evaluation of Fixed-Dose Daptomycin in Obese Patients With Bloodstream Infections Caused by Staphylococcus aureus
    Lorenzo, Michael P.
    Housman, Erica L.
    Housman, Seth T.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (03) : 290 - 291
  • [48] Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus
    Sader, Hello S.
    Jones, Ronald N.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2012, 73 (02) : 212 - 214
  • [49] Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013)
    Sader, Helio S.
    Farrell, David J.
    Flamm, Robert K.
    Jones, Ronald N.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2015, 3 (03) : 161 - 165
  • [50] In vitro efficacy of Daptomycin against clinical isolates of Methicillin-resistant Staphylococcus aureus (MRSA)
    Shah, Asim Ali
    Abbasi, Shahid Ahmad
    Ali, Yasir
    Maqbool, Ayesha
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (01) : 338 - 340